Bellevue Life Sciences Acquisition Corp.
A blank-check company that raised money to acquire a healthcare business, Bellevue Life Sciences was created in 2020 by a team tied to Bellevue Capital Management, a Washington State investment firm — hence its name. In February 2025 it merged with South Korea's OSR Holdings, becoming OSR Health, Inc., which trades on Nasdaq and develops oral cancer vaccines through its Vaximm subsidiary.
Warrant (redeemable for common stock at 1.50/share)